New stem cell approach targets functional cure for diabetes - News-Medical
A new immune-engineered stem cell approach is targeting a functional cure for Type 1 diabetes by eliminating the need for immunosuppression.
📍 How it ended
Researchers have been exploring a new stem cell approach targeting a functional cure for diabetes, with companies like Sana Biotechnology making progress in the field. A first human trial has begun for an immune-engineered cell therapy for type 1 diabetes, and follow-on publication in The New England Journal of Medicine highlighted long-term data on hypoimmune-modified islet cell transplantation. The story quieted without further recent developments.
Epilogue added 44d ago, after coverage quieted.
Questions people are asking
What is the primary goal of this new stem cell approach?
The approach targets a functional cure for Type 1 diabetes.
Which company is providing updates on this therapy?
Sana Biotechnology is providing updates and has published data in The New England Journal of Medicine.
Does this treatment require immunosuppression?
According to coverage from The Manila Times, the hypoimmune-modified islet cell transplantation functions without immunosuppression.
What happened
Researchers are exploring a new stem cell approach and immune-engineered cell therapy to treat Type 1 diabetes. This method involves hypoimmune-modified islet cell transplantation, designed to help transplanted cells thrive and provide long-term durability without the use of immunosuppressant drugs.
Coverage from News-Medical, Bioengineer.org, and Newswise emphasizes the pursuit of a functional cure and the mechanisms used to protect transplanted cells. The Manila Times reports that Sana Biotechnology has published long-term data and durability results in The New England Journal of Medicine (NEJM).
Attention is now on Sana Biotech, which is heading to the European Association for the Study of Diabetes (EASD) to provide an update on the cell therapy.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 45d ago.
Coverage (5)
- First Human Trial Explores Immune-Engineered Cell Therapy for Type 1 Diabetes Bioengineer.org · 48d ago
- Sana Biotech heads to EASD with diabetes cell therapy update Longevity.Technology · 48d ago
- New Research Seeks to Help Transplanted Cells Thrive in Type 1 Diabetes Treatment Newswise · 48d ago
- Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 D The Manila Times · 48d ago
- New stem cell approach targets functional cure for diabetes News-Medical · 48d ago broke it first
The coverage curve
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
People, places & organizations
Topics
Related trends
The data that led an AI biotech to pick up Novo's Parkinson's stem cell therapy
An AI biotech firm has acquired Novo's Parkinson's stem cell therapy following promising data from initial human trials.